These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20801656)

  • 21. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
    Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
    Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ).
    Horiuchi K; Morioka H; Nishimoto K; Suzuki Y; Susa M; Nakayama R; Kawai A; Sonobe H; Takaishi H; Ozaki T; Yabe H; Umezawa K; Toyama Y
    Cancer Lett; 2008 Dec; 272(2):336-44. PubMed ID: 18760530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Ueki S; Yamashita K; Aoyagi T; Haga S; Suzuki T; Itoh T; Taniguchi M; Shimamura T; Furukawa H; Ozaki M; Umezawa K; Todo S
    Transplantation; 2006 Dec; 82(12):1720-7. PubMed ID: 17198266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines.
    Ohsugi T; Kumasaka T; Okada S; Ishida T; Yamaguchi K; Horie R; Watanabe T; Umezawa K
    Cancer Lett; 2007 Nov; 257(2):206-15. PubMed ID: 17764832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
    Wakamatsu K; Nanki T; Miyasaka N; Umezawa K; Kubota T
    Arthritis Res Ther; 2005; 7(6):R1348-59. PubMed ID: 16277688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells.
    Wong JH; Lui VW; Umezawa K; Ho Y; Wong EY; Ng MH; Cheng SH; Tsang CM; Tsao SW; Chan AT
    Cancer Lett; 2010 Jan; 287(1):23-32. PubMed ID: 19560263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of human dendritic cells by a novel specific nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Shinoda K; Nakagawa K; Kosaka T; Tanaka N; Maeda T; Kono H; Mizuno R; Kikuchi E; Miyajima A; Umezawa K; Oya M
    Hum Immunol; 2010 Aug; 71(8):763-70. PubMed ID: 20573582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiogenesis inhibitor epoxyquinol a: total synthesis and inhibition of transcription factor NF-kappaB.
    Li C; Bardhan S; Pace EA; Liang MC; Gilmore TD; Porco JA
    Org Lett; 2002 Sep; 4(19):3267-70. PubMed ID: 12227765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and synthesis of biotinylated DHMEQ for direct identification of its target NF-κB components.
    Saitoh T; Takeiri M; Gotoh Y; Ishikawa Y; Umezawa K; Nishiyama S
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6293-6. PubMed ID: 21945203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, prevents inflammatory injury induced by interferon-gamma and histamine in NCTC 2544 keratinocytes.
    Cardile V; Libra M; Caggia S; Frasca G; Umezawa K; Stivala F; Mazzarino MC; Bevelacqua Y; Coco M; Malaponte G
    Clin Exp Pharmacol Physiol; 2010 Jul; 37(7):679-83. PubMed ID: 20337659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia.
    Ohsugi T; Horie R; Kumasaka T; Ishida A; Ishida T; Yamaguchi K; Watanabe T; Umezawa K; Urano T
    Carcinogenesis; 2005 Aug; 26(8):1382-8. PubMed ID: 15831528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of NO-induced β-cell death by novel NF-κB inhibitor (-)-DHMEQ via activation of Nrf2-ARE pathway.
    Ogasawara A; Simizu S; Ito A; Kawai T; Saisho Y; Takei I; Umezawa K
    Biochem Biophys Res Commun; 2013 Apr; 433(2):181-7. PubMed ID: 23454127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemoenzymatic synthesis of (2R,3R,4R)-dehydroxymethylepoxyquinomicin (DHMEQ), a new activator of antioxidant transcription factor Nrf2.
    Niitsu Y; Hakamata M; Goto Y; Higashi T; Shoji M; Sugai T; Umezawa K
    Org Biomol Chem; 2011 Jun; 9(12):4635-41. PubMed ID: 21541373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antineoplastic Effects of NF-κB Inhibition by DHMEQ (Dehydroxymethylepoxyquinomicin) Alone and in Co-treatment with Radio-and Chemotherapy in Medulloblastoma Cell Lines.
    Ramos PMM; Pezuk JA; Castro-Gamero AM; Oliveira HF; Scrideli CA; Umezawa K; Tone LG
    Anticancer Agents Med Chem; 2018; 18(4):541-549. PubMed ID: 29141555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic effect of 5-azacytidine and NF-κB inhibitor DHMEQ on apoptosis induction in myeloid leukemia cells.
    Togano T; Nakashima M; Watanabe M; Umezawa K; Watanabe T; Higashihara M; Horie R
    Oncol Res; 2012; 20(12):571-7. PubMed ID: 24139415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and evaluation of a cyclopropane derivative of DHMEQ.
    Yasui E; Takayama K; Nakago T; Takeda N; Imamura Y; Nagumo S
    Chem Pharm Bull (Tokyo); 2014; 62(3):304-7. PubMed ID: 24369292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
    Katsman A; Umezawa K; Bonavida B
    Drug Resist Updat; 2007; 10(1-2):1-12. PubMed ID: 17306602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
    Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice.
    Kikuchi E; Horiguchi Y; Nakashima J; Kuroda K; Oya M; Ohigashi T; Takahashi N; Shima Y; Umezawa K; Murai M
    Cancer Res; 2003 Jan; 63(1):107-10. PubMed ID: 12517785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells.
    Togano T; Sasaki M; Watanabe M; Nakashima M; Tsuruo T; Umezawa K; Higashihara M; Watanabe T; Horie R
    Biochem Biophys Res Commun; 2009 Dec; 390(1):60-4. PubMed ID: 19778522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.